Many patients seek treatment in their late 20s to early 40s, but suitability depends on anatomy, volume loss, and aesthetic goals.
Common GLP-1 receptor agonists: Semaglutide (Ozempic, Wegovy, Rybelsus) Liraglutide (Victoza, Saxenda) Dulaglutide (Trulicity) Tirzepatide (Mounjaro, Zepbound)* Exenatide (Byetta, Bydureon) Lixisenatide (Adlyxin) *Tirzepatide is technically a dual GIP/GLP-1 receptor agonist but is often grouped with GLP-1 medications
One night on the counter falls well within that window
Studies show that individual response to GLP-1 varies, and without lifestyle changes, Semaglutide alone may not lead to consistent or expected results
Change history 05 June 2026 The online version of this article has been updated to correct errors in the reference citations